Table 7.
After 3 months | After 6 months | |||
---|---|---|---|---|
Observed changes | Adjusted changes | Observed changes | Adjusted changes | |
QLQ-C30 | ||||
Global Health Status | 16 | 12a | 0.5 | 8a |
Physical functioning | 12 | 12a | 0.4 | 9a |
Role functioning | 26 | 19a | 2 | 18a |
Cognitive functioning | 5 | 11a | 1 | 10a |
Social functioning | 20 | 15a | 1 | 10a |
Emotional functioning | 3.5 | 6a | 0.5 | 6a |
Fatigue | 27 | 23a | 0.2 | 20a |
Pain | 14 | 9a | 2 | 17a |
Dyspnea | 9 | 11a | 4 | 8a |
Insomnia | 6 | 8a | 4 | 15a |
Financial difficulties | 10 | 8a | 3 | 5a |
Appetite loss | 10 | 11a | 10 | 4 |
Constipation | 15 | 10a | 1 | 3 |
Nausea and vomiting | 9 | 8a | 3 | 1 |
QLQ-BR23 | ||||
Body image | 20 | 15a | 0.4 | 11a |
Sexual functioning | 7 | 7a | 0.4 | 11a |
Systemic therapy side effects | 19 | 20a | 3 | 10a |
Breast symptoms | 14 | 18a | 4 | 6a |
Arm symptoms | 8 | 9a | 0.6 | 11a |
Sexual enjoyment | 14 | 12a | 13 | 15a |
Future perspectives | 7 | 9a | 3 | 0.7 |
a indicates that the MID stayed or became greater than 5 points when the response shift effect was taken into account